GRAIL, Inc. (GRAL)
NASDAQ: GRAL · Real-Time Price · USD
61.11
-0.99 (-1.59%)
At close: Jun 23, 2026, 4:00 PM EDT
61.13
+0.02 (0.03%)
After-hours: Jun 23, 2026, 6:43 PM EDT

Company Description

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.

It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer.

The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development.

In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring.

The company was incorporated in 2015 and is headquartered in Menlo Park, California.

GRAIL, Inc.
GRAIL logo
CountryUnited States
Founded2016
IndustryDiagnostics & Research
SectorHealthcare
Employees910
CEOJoshua Ofman

Contact Details

Address:
1525 O’Brien Drive
Menlo Park, California 94025
United States
Phone833 694 2553
Websitegrail.com

Stock Details

Ticker SymbolGRAL
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code1699031
CUSIP Number384747101
ISIN NumberUS3847471014
Employer ID86-3673636
SIC Code8071

Key Executives

NamePosition
Robert P. RagusaAdvisor
Paul CiccolellaSenior Vice President of Global Development and Operations
Abram Barth J.D., M.P.H.Chief Legal Officer and Corporate Secretary
Alison HighlanderSenior Vice President of Human Resources and Head of People Team
Dr. Satnam Alag Ph.D.Senior Vice President of Software Engineering and Chief Security Officer
Dr. Eric T. Fung M.D., Ph.D.Senior Vice President of Clinical Development
Erin PolakSenior Vice President of Government Affairs, Policy, and Alliance Development

Latest SEC Filings

DateTypeTitle
Jun 22, 20268-KCurrent Report
Jun 3, 2026144Filing
Jun 1, 20268-KCurrent Report
May 15, 2026SCHEDULE 13G/AFiling
May 11, 2026SCHEDULE 13G/AFiling
May 7, 202610-QQuarterly Report
May 5, 20268-KCurrent Report
Apr 28, 2026DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 28, 2026DEF 14AOther definitive proxy statements
Apr 6, 2026144Filing